A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Hepatitis B Virus Infection

In brief

The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.

Key facts

Study ID
NCT07024641
Run by
GigaGen, Inc.
People needed
48
Starts
2024-11-13
Expected to finish
2028-11-01
Last updated by the study team
2026-07-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.